Disease Prevention Panel updated and expanded to include diabetes module

As part of the regular panel updates, CeGaT has updated and expanded the Disease Prevention Panel. The panel now also covers forms of genetic diabetes mellitus and offers a wider diagnostic spectrum in the field of pharmacogenetics.

Genetic risk factors play an important role in many diseases occurring in our society. CeGaT’s prevention panel examines genetic risk factors for various diseases, such as cancer or cardiovascular diseases. If an individual risk for a disease is known, a timely action can be taken to prevent or delay the outbreak or progression of a disease.

New module identifies diabetes dispositions – the starting point for preventive measures

The new module “Diabetes” covers five genes that are associated with an increased risk for familial diabetes mellitus. Diabetes mellitus (diabetes) describes a group of diseases manifested by elevated blood glucose levels. In the development of familial diabetes mellitus genetic plays a central role. Maturity-Onset Diabetes of the Young (MODY), analyzed in the Prevention Panel, can be diagnosed partly in adolescence and partly in adulthood. During the course of the disease, microvascular complications such as damage to the kidneys, eyes, and nerves may occur.

If the patient has a predisposition to diabetes, appropriate preventive measures can be initiated. Depending on the type of disease, therapy consists of lifestyle adjustments such as dietary changes and, if necessary, drug treatment.

Expansion of the Pharmacogenetics Module

Pharmacogenetics deals with a person’s individual, genetically determined drug metabolism. Not everyone processes medications in the same way – what helps one person may be ineffective or even harmful in another. The Pharmacogenetics Module of the Prevention Panel determines whether active ingredients are broken down particularly quickly or very slowly. With the update of the panel, the ABCG2 and G6PD genes were added to the module. This has expanded the diagnostic spectrum in the area of antibiotics, antidiabetics, statins, and in the treatment of acute hyperuricemia kidney failure. Based on the test results, the physician can select a suitable drug and administer the correct dosage. This also applies to future therapies.

The new panel can be requested here.

For further information, please do not hesitate to contact us at diagnostic-support@cegat.com.Find Out More!